Introduction
============

Complicated infections often require a long antibiotic therapy period. Especially in diseases such as osteomyelitis, skin and soft tissue infections or endocarditis, antibiotic durations up to 3--6 weeks are possible \[[@R1]\], \[[@R2]\], \[[@R3]\], \[[@R4]\], \[[@R5]\], \[[@R6]\], \[[@R7]\], \[[@R8]\]. Patients with Methicillin-resistant *Staphylococcus aureus* (MRSA) infections stay in hospital for even longer \[[@R9]\], \[[@R10]\]. As hospitals in Germany are funded by diagnosis-related group (DRG) payments per case, the length of stay (LOS) has become a critical economic factor \[[@R11]\], \[[@R12]\], \[[@R13]\], \[[@R14]\], \[[@R15]\], \[[@R16]\]. With this in mind, reducing the LOS seems to be an economically viable option. Studies show that early discharge and outpatient continuation of antibiotic therapy, for example by oralization, may lead to savings \[[@R17]\], \[[@R18]\], \[[@R19]\], \[[@R20]\]. Oralization is often accompanied by problems related to patients' compliance. Other problems are that sometimes because of intolerance or resistance, no oral option is available. With Dalbavancin, however, a novel antimicrobial agent is available that enables an intravenous single-dose with an extremely extended half-life in Gram-positive bacteria. Dalbavancin thus gives clinicians the opportunity to provide an antibiotic that is proven to be as effective as conventional therapies without the need for prolonged hospitalization drastically reducing the LOS and the total cost per patient \[[@R21]\]. The aim of this study is to determine the economic effects that could be achieved by single-dose intravenous Dalbavancin in suitable patients with MRSA infections in Germany.

Methods
=======

In Germany, inpatient cases are reimbursed using a fee-per-case system (DRG system) based on the principle "same money for same service". This poses a challenge for hospitals as cost-covering performance can only be provided up to a certain point in time after which the costs exceed the revenues. The calculation basis of the Institute for Hospital Reimbursement (InEK) is the average cost per DRG of all hospitals participating in this calculation. For each DRG, LOS thresholds are defined as the lower trimpoint LOS (ltpLOS), average LOS (aLOS) and upper trimpoint LOS (htpLOS) \[[@R16]\], \[[@R22]\], \[[@R23]\], \[[@R24]\]. If the average LOS is exceeded, the patient\'s LOS represents a cost driver for the hospital within the DRG system. Patients with MRSA infections often have significantly longer LOS and are therefore above the average lengths of hospital stay. Exceeding the LOS is associated with increased costs, which is why these patients cause a loss for the hospital \[[@R25]\], \[[@R26]\], \[[@R27]\].

In order to evaluate possible cost savings, an economic model was developed based on the assumption that there is a cohort of patients with MRSA infections who are basically dischargeable but only remain in hospital for the administration of a necessary intravenous antibiotic therapy. Using the example of Dalbavancin, an antimicrobial agent for the treatment of acute bacterial skin, skin structure and soft tissue infections (ABSSSI) in gram-positive pathogens, it was calculated to what extent a hospital could benefit from shortening the inpatient stay of suitable patients.

With a terminal half-life of \>14 days, Dalbavancin can be administered via an intravenous single-dose of 1,500 mg \[[@R28]\] which enables the hospital to discharge the patient under the protection of an optimal antibiotic therapy. Dalbavancin thus provides a dosing regimen with infrequent parenteral administration to treat infectious diseases that otherwise require daily intravenous therapy for many weeks \[[@R28]\]. To estimate possible savings through single-dose intravenous Dalbavancin in patients with MRSA infections, clinical entities that are often associated with MRSA infections and that bare the option of early discharge were described. For the ABSSSI group, we used the FDA definitions \[[@R29]\]. On top of these, we defined a group of joint, bone and prostheses infections (JBPI), where infection treatment is often long and single-dose administration could be a tool for shortening LOS in hospital. Table 1 [(Tab. 1)](#T1){ref-type="fig"} shows the classification of the entities. A table that includes the ICD-10 codes used is provided in [Attachment 1](#SD1){ref-type="supplementary-material"}.

As infections and especially infection with MRSA negatively impact the LOS of patients, we needed data to compare the aLOS of the DRG -- which is always a mix of patients with no infections, with infections and with MRSA infections as most DRGs are not specifically designed for infection patients -- with the LOS of infection patients and MRSA infection patients in the respective infection groups. This analysis was done on a large benchmarking database, in which 300 hospitals participated and about four million cases are registered annually. In order to understand the variation, all cases in the above-mentioned infection groups from 2016 were analysed \[[@R30]\].

To assess possible savings, a 3:1 propensity score matching was performed. Matched were the infection cases with MRSA infection cases against infections without MRSA from the two groups (ABSSSI and JBPI) using age, sex, principle diagnosis, DRG and comorbidities (via Charlson Comorbidity Index -- CCI) in order to control confounders for costs, using a caliper of 0.1. The difference in costs and aLOS were then analysed.

According to the literature, the proportion of patients with ABSSSI who could be discharged earlier through oralization is 37.9 percent \[[@R17]\]. Within the model, it was assumed that the same proportion of patients who could potentially receive single-dose intravenous Dalbavancin also applies to wound infections. Therefore we assumed that 37.9 percent of all MRSA patients could benefit from single-dose intravenous Dalbavancin.

The difference in costs between infections without and with MRSA was taken as possible savings. The total result was calculated by taking into account these savings as well as adding the treatment costs (2,280 € per 1,500 mg dose).

After the analysis the proportion of patients and the shortening of LOS were validated by a case-review in a large major urban hospital.

Results
=======

Case data from 171,074 patients in the respective infection groups have been analysed. Table 2 [(Tab. 2)](#T2){ref-type="fig"} shows the distribution of cases before and after 3:1 propensity score matching.

The results of detailed analysis per infection group are shown in Table 3 [(Tab. 3)](#T3){ref-type="fig"} and Table 4 [(Tab. 4)](#T4){ref-type="fig"}.

The analysis of real-world cases shows that in ABSSSI the presence of MRSA leads to excess costs of 5,145 € and a prolongation in LOS of 6.45 days, while in JBPI the excess costs of MRSA are even higher with 6,189 € and additional LOS of 10.59 days. Overall, the use of single-dose intravenous Dalbavancin and early discharge has the potential to create an average saving of 2,964 € as shown in Table 5 [(Tab. 5)](#T5){ref-type="fig"}.

The weighted LOS difference in ABSSSI and JBPI was 6.8 days.

The peer review of MRSA infection cases in a major urban hospital was conducted to validate the results of the data analysis. Of 211 MRSA patients, 108 were carriers and had no infection. Of the remaining 103 cases, 47 patients had underlying conditions that would potentially make them suitable for single-dose intravenous Dalbavancin and subsequent discharge. Of these 47 cases, 32 percent could have been released. In average, LOS would have been 8.5 (varying from 4--18) days shorter. The savings calculated in this patient group were 2,281 €.

Discussion
==========

The health economic analysis shows that cost savings can be achieved by administering single-dose intravenous Dalbavancin in patients with MRSA infections. The results are in line with other studies that have investigated the economic effects of Dalbavancin \[[@R31]\], \[[@R32]\], \[[@R33]\]. Single-dose intravenous Dalbavancin shortens the LOS and thus results in cost savings.

MRSA incidence was 10.8 percent for ABSSSI and 11.3 percent for JBPI. The incidence of MRSA has remained steady in German hospitals. A slight decline from 0.71 percent in 2013 to 0.69 percent in 2016 was recorded for the overall MRSA rate in Germany according to Destatis. Nevertheless, 131,014 of 18,959,832 inpatients in Germany had MRSA as a pathogen coded \[[@R34]\]. The Antibiotic Resistance Surveillance (ARS) at the Robert Koch Institute (RKI) determined an MRSA prevalence of 12.1 percent in 2015 and 10.6 percent in 2016 for blood cultures from inpatient care \[[@R35]\]. Although national MRSA percentages vary widely between 1.2 percent and 50.5 percent \[[@R36]\], MRSA isolation in ABSSSI can be as high as 25 percent in Europe \[[@R37]\]. Our findings are in line with other sources.

Although outpatient parenteral antibiotic therapy (OPAT) has not yet been established in Germany, it provides a theoretical option for avoiding or reducing an inpatient stay. However, it cannot be considered appropriate for all patients as some of them may be unable to travel to receive their treatment \[[@R38]\], \[[@R39]\], \[[@R40]\]. Likewise, the possibility of oralization is not suitable for all patients who are eligible for discharge. A key factor here is the patients' compliance. Studies show that the compliance of patients depends on various factors and is often low \[[@R41]\], \[[@R42]\], \[[@R43]\]. For example, Eells et al. state that patient adherence to oral antibiotic therapy for SSTI after hospital discharge was only 57 percent, which was associated with poor clinical outcomes \[[@R43]\]. Thus, a single-dose intravenous Dalbavancin is an option for patients where the LOS can be significantly reduced.

Routine data was used to calculate savings estimates. These were derived from the cost difference of patients with or without MRSA infection. This is admittedly a crude estimate and may differ in clinical reality. The validation in a major urban hospital showed that 32% of the patients were eligible for discharge. This is less than the findings of Eckmann et al. \[[@R17]\], who reported a discharge opportunity rate of 47 percent in Germany and 37.9 percent in the entire study. However, the peer-review of the hospital cases carried out in the context of this paper revealed possible savings of 8.5 days, while Eckmann et al. found savings of only 6.2 bed days per case. This implies that findings will probably vary from hospital to hospital.

The achievable savings in the validation group of 2,281 € were close to our calculation of 2,964 €. This can be an indicator that the estimates used were solid. However, for compliant patients that tolerate oral antibiotics the savings would be 5,244 € in average. That again is close to the measured cost differences in the two groups of ABSSSI and JBPI. The savings are calculated using the average cost difference. Therefore no 95% CI for the calculated effect is available. The challenge in calculating savings is to pick the right patients. The assumption to apply the possible average savings to 37.9% of all MRSA patients is currently investigated in a prospective evaluation of the use of Dalbavancin i.v. in a tertiary care hospital.

Moreover, extended LOS in hospital is known to be an independent risk factor for the increase of hospital acquired infections \[[@R44]\], \[[@R45]\], \[[@R46]\]. Therefore, reducing LOS through early discharge has clinical and economical benefits.

Applying antibiotics with a half-life of 14 days or more can imply a risk for possible adverse effects. The available data on Dalbavancin show a good safety profile with nausea (2.4 %), diarrhoea (1.9 %), and headache (1.3 %) being the only common side effects according to SmPC and generally of mild or moderate severity \[[@R47]\]. A meta-analysis by Dunne et al. showed less treatment-related adverse events and severe adverse events than comparators from phase 2/3 clinical trials with agents including vancomycin, linezolid, cefazolin, nafcillin, or oxacillin. The duration of adverse events proved to be not longer than with short-acting antibiotics (median 3.0 days Dalbavancin vs. 4.0 days comparators), nor did it take longer until the adverse events occurred (median 3.0 days Dalbavancin vs. 3.0 days comparators) \[[@R48]\].

Conclusion
==========

The LOS of patients with MRSA ABSSSI and JBPI infections is substantially higher than in patients with infections without MRSA in the respective DRGs and causes significant extra costs. Therefore, single-dose intravenous Dalbavancin may be an attractive option for dischargeable patients with MRSA infections who would otherwise be ineligible for OPAT or oralization due to factors such as lack of social support, frailty or substance misuse \[[@R40]\], \[[@R49]\], \[[@R50]\], \[[@R51]\], \[[@R52]\], \[[@R53]\]. Patients with an expectedly long intravenous antibiotic therapy (6--10 days) and no other reason to stay in hospital could be selected.

Notes
=====
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